Hims & Hers planning to sell compounded peptides
Hims & Hers Health is planning to sell compounded peptides, the company said in a Monday earnings call. The company’s CEO, Andrew Dudum, said in the earnings call that it was “currently developing a best-in-class peptides experience, including U.S. manufactured products, clinical-led guidance, and ongoing blood testing.” Dudum said in the call that the company...
We haven't written up this one. The Hill has the full story — the link below goes straight to it.
